Skip to main content
SpringerLink
Log in

Pankreaskarzinom

Best supportive care of pancreatic carcinoma

  • Schwerpunkt: Palliative Tumortherapie im Verdauungstrakt
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Das duktale Adenokarzinom des Pankreas (Pankreaskarzinom) hat eine Inzidenz von ca. 10.000 Fällen pro Jahr in Deutschland. Die Erkrankung ist nur bei jedem 5. Patient bei Diagnosestellung noch in einem operablen Stadium, die 5-Jahres-Überlebensrate aller Patienten liegt unter 5%. Schmerzen, Kachexie, Ikterus, Übelkeit, Fatigue und Depression treten im Krankheitsverlauf häufig auf und schränken die Lebensqualität der Patienten erheblich ein. Das vorrangige Ziel der palliativen Behandlung liegt in der Besserung der Lebensqualität. Durch zytostatische Therapiekonzepte kann allenfalls eine moderate Verlängerung der Lebenszeit erreicht werden. Gemcitabin ist derzeit der Standard in der Therapie des metastasierten Pankreaskarzinoms. Eine Radiochemotherapie kommt bei lokal fortgeschrittenen Tumoren in Betracht. Alternative Therapieverfahren werden aktuell in Studien untersucht.

Abstract

The incidence of pancreatic cancer is about 10,000 cases a year in Germany. The role of surgery as a curative modality is limited. The 5-year survival for all stages remains less than 5%. Pain, cachexia, jaundice, nausea, fatigue and depression are frequent symptoms which reduce the quality of life for affected patients. Therefore, amelioration of symptoms is a major goal of palliative care. Chemotherapy may yield a moderate survival benefit. Gemcitabine is the drug of choice in metastatic pancreatic cancer. In locally advanced disease, radiochemotherapy can be considered. Different treatment strategies against molecular targets are currently tested in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1a, b
Abb. 2

Literatur

  1. Arbeitsgemeinschaft bevölkerungsbezogener Krebsregister in Deutschland (2002) Krebs in Deutschland. Häufigkeiten und Trends, 3. Aufl.

  2. DiMagno EP, Reber HA, Tempero MA (1999) AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117: 1464–1484

    CAS  PubMed  Google Scholar 

  3. Fischer L, Friess H, Z’graggen K, Uhl W, Büchler MW (2003) Operative management in the treatment of pancreatic cancer. Zentralbl Chir 128: 390–395

    Article  CAS  PubMed  Google Scholar 

  4. Smith AC, Dowsett JF, Russell RCG, Hatfield ARW, Cotton PB (1994) Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet 344: 1655–1660

    CAS  PubMed  Google Scholar 

  5. Speer AG, Cotton PB, Russell RC et al. (1987) Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 11: 57–62

    Article  Google Scholar 

  6. Knyrim K, Wagner HJ, Pausch J, Vakil N (1993) A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. Endoscopy 25: 207–212

    CAS  PubMed  Google Scholar 

  7. Prat F, Chapat O, Ducot B et al. (1998) A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 47: 1–7

    CAS  PubMed  Google Scholar 

  8. Wigmore SJ, Plester CE, Richardson RA, Fearon KC (1997) Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75: 106–109

    CAS  PubMed  Google Scholar 

  9. Tisdale MJ (1999) Wasting in cancer. J Nutr 129 (Suppl): 243S–246S

    CAS  PubMed  Google Scholar 

  10. Perez MM, Newcomer AD, Moertel GG et al. (1983) Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer 52: 346–352

    CAS  PubMed  Google Scholar 

  11. Jatoi Jr A, Loprinzi CL (2001) Current management of cancer-associated anorexia and weight loss. Oncology 15: 497–502

    PubMed  Google Scholar 

  12. McGeer AJ, Detsky AS, O’Rourke K (1990) Parenteral nutrition in cancer patients undergoing chemotherapy: a meta analysis. Nutrition 6: 233–240

    CAS  PubMed  Google Scholar 

  13. Wigmore SJ, Barber MD, Ross, JA, Tisdale MJ, Fearon KC (2000) Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36: 177–184

    CAS  PubMed  Google Scholar 

  14. Lillemoe KD, Cameron JL, Hardacre JM et al. (1999) Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 230: 328–330

    Google Scholar 

  15. Yim HB, Jacobson BC, Saltzman JR et al. (2001) Clinical outcome of the use of enteral stents for palliation of patients with malignant upper GI obstruction. Gastrointest Endosc 53: 329–332

    CAS  PubMed  Google Scholar 

  16. Schiefke I, Zabel-Langhennig A, Wiedmann M et al. (2003) Self-expandable metallic stents for malignant duodenal obstruction caused by biliary tract cancer. Gastrointest Endosc 58: 213–219

    PubMed  Google Scholar 

  17. Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PK (1993) Chemical splanchnicectomy in patients with unresectable pancreatic cancer: a prospective randomized trial. Ann Surg 217: 447–457

    CAS  PubMed  Google Scholar 

  18. Wong GY, Schroeder DR, Carns PE et al. (2004) Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 291: 1092–1099

    Article  CAS  PubMed  Google Scholar 

  19. Kelsen DP, Portenoy RK, Thaler HT et al. (1995) Pain and depression in patients with newly diagnosed pancreatic cancer. J Clin Oncol 13: 748–755

    CAS  PubMed  Google Scholar 

  20. Berger A (2003) Treating fatigue in cancer patients. Oncologist 8 (Suppl): 10–14

    Google Scholar 

  21. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874

    CAS  PubMed  Google Scholar 

  22. Lee AYY, Levine MN, Baker RI et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146–153

    CAS  PubMed  Google Scholar 

  23. Patel L, Lindley C (2003) Aprepitant—a novel NK1-receptor antagonist. Expert Opin Pharmacother 4: 2279–2296

    Article  CAS  PubMed  Google Scholar 

  24. Moertel CG, Frytak S, Hahn RG et al. (1981) Therapy of locally unresectable pancreatic carcinoma: a randomised comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumour Study Group. Cancer 48: 1705–1710

    CAS  PubMed  Google Scholar 

  25. Crane CH (2001) Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 29: 9–18

    Article  CAS  PubMed  Google Scholar 

  26. Li CP, Chao Y, Chi KH et al. (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57: 98–104

    Article  CAS  PubMed  Google Scholar 

  27. Wilkowski R, Thoma M, Heinemann V, Rau HG, Wagner A, Stoffregen C, Duhmke E (2003) Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer—feasible and effective. Strahlenther Onkol 179: 78–86

    Article  PubMed  Google Scholar 

  28. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 3: 373–378

    CAS  PubMed  Google Scholar 

  29. GITSG (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 80: 751–755

    PubMed  Google Scholar 

  30. Kelsen D, Hudis C, Niedzwiecki D et al. (1991) A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68: 965–969

    CAS  PubMed  Google Scholar 

  31. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81: 882–885

    CAS  PubMed  Google Scholar 

  32. Burris HA, Moore MJ, Andersen J et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomised trial. J Clin Oncol 15: 2403–2413

    PubMed  Google Scholar 

  33. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402–3408

    Article  PubMed  Google Scholar 

  34. Colucci G, Giuliani F, Gebbia V et al. (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer 94: 902–910

    Article  CAS  PubMed  Google Scholar 

  35. Heinemann V, Quietzsch D, Gieseler F et al. (2003) A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 22: 250 (A1003)

    Google Scholar 

  36. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2997. J Clin Oncol 20: 3270–3275

    Article  CAS  PubMed  Google Scholar 

  37. Rocha Lima CMS, Rotche R et al. (2003) A randomized phase III study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc Am Soc Clin Oncol 22: 251 (A1005)

    Google Scholar 

  38. Bramhall SR, Schulz J, Nemunaitis J, Brown, PD, Baillet M, Buckels JA (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161–167

    Article  CAS  PubMed  Google Scholar 

  39. Van Cutsem E, Krasek P, Oettle H et al. (2002) Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer. Proc Am Soc Clin Oncol 21: A517

    Google Scholar 

Download references

Danksagung

Wir danken Prof. Dr. Stefan Rosewicz, Humboldt-Universität Berlin, Charité, Campus Virchowklinikum für wertvolle Anmerkungen und die kritische Durchsicht des Manuskripts.

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik II, Universitätsklinikum Leipzig

    K. Schoppmeyer &  J. Mössner

  2. Zentrum für Innere Medizin, Medizinische Klinik und Poliklinik II, Universitätsklinikum Leipzig AöR, Philipp-Rosenthal-Straße 27, 04103, Leipzig

    J. Mössner

Authors
  1. K. Schoppmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Mössner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Mössner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schoppmeyer, K., Mössner, J. Pankreaskarzinom. Internist 45, 769–776 (2004). https://doi.org/10.1007/s00108-004-1222-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-004-1222-7

Schlüsselwörter

Keywords

Search

Navigation